Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.

IF 2.7 4区医学 Q3 ONCOLOGY

Cancer Chemotherapy and Pharmacology Pub Date : 2024-04-01 Epub Date: 2023-11-28 DOI:10.1007/s00280-023-04619-3

Hiroaki Takahashi, Yoko Saito, Kanon Sugawara, Masaki Sato, Tomohiko Tairabune, Haruki Ujiie, Junichi Asaka, Kenzo Kudo

{"title":"Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.","authors":"Hiroaki Takahashi, Yoko Saito, Kanon Sugawara, Masaki Sato, Tomohiko Tairabune, Haruki Ujiie, Junichi Asaka, Kenzo Kudo","doi":"10.1007/s00280-023-04619-3","DOIUrl":null,"url":null,"abstract":"Purpose: Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders.Methods: This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication.Results: The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: \"Grade 1 and lower,\" and \"Grade 2 and higher.\" The skin parameters were compared between these groups. The results showed that in the \"Grade 2 and higher\" group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the \"Grade 1 and lower\" group. However, the two groups showed no significant differences in hydration or sebum levels at any time point.Conclusion: TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.","PeriodicalId":9556,"journal":{"name":"Cancer Chemotherapy and Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Chemotherapy and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00280-023-04619-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders.

Methods: This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication.

Results: The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: "Grade 1 and lower," and "Grade 2 and higher." The skin parameters were compared between these groups. The results showed that in the "Grade 2 and higher" group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the "Grade 1 and lower" group. However, the two groups showed no significant differences in hydration or sebum levels at any time point.

Conclusion: TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.

Abstract Image

查看原文本刊更多论文

帕尼珠单抗致皮肤病的定量评估:一项前瞻性观察性研究。

目的:痤疮样皮疹在接受抗表皮生长因子受体(EGFR)抗体药物治疗的癌症患者中经常观察到，并且通常需要停药。然而，抗egfr抗体药物给药引起的皮肤参数的具体变化尚不清楚。因此，本研究旨在纵向定量评价抗egfr抗体药物引起的皮肤参数(经皮失水[TEWL]、水合水平和皮脂水平)的变化，并探讨其作为皮肤疾病对照标志物的潜力。方法:本前瞻性研究纳入12例首次接受抗egfr抗体药物治疗的结直肠癌患者。评估项目包括痤疮皮疹的等级和皮肤参数(TEWL、水合水平和皮脂水平)，这些在给药后观察长达6周。结果:入选患者根据抗egfr抗体药物引起的痘样皮疹的分级分为“1级及以下”和“2级及以上”两组。比较各组皮肤参数。结果显示，“二级及以上”组患者面部(给药2周)、胸部(基线、给药2周、给药6周)、背部(给药2周)TEWL均显著高于“一级及以下”组。然而，两组在任何时间点的水合作用或皮脂水平都没有显着差异。结论:TEWL可作为肿瘤治疗中抗egfr抗体药物引起的痤疮样皮疹的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Chemotherapy and Pharmacology 医学-药学

CiteScore

6.10

自引率

3.30%

发文量

116

审稿时长

2.5 months

期刊介绍： Addressing a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels, Cancer Chemotherapy and Pharmacology is an eminent journal in the field. The primary focus in this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. It is essential reading for pharmacologists and oncologists giving results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy.